Newswire (Published: Monday, May 1, 2017, Received: Friday, April 28, 2017, 12:23:59 AM CDT)

Word Count: 582

Findings on Prostate Cancer Discussed by Investigators at Department of Urology (Active Surveillance for Favorable Risk Prostate Cancer in African Caribbean Men: Results of a Prospective Study)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting out of Pointe a Pitre, Guadeloupe, by NewsRx editors, research stated, "Active surveillance is a treatment option for favorable risk prostate cancer. However, data are missing on populations of African descent."

Our news journalists obtained a quote from the research from the Department of Urology, "We evaluated the safety and benefit of active surveillance in an African Caribbean cohort with favorable risk prostate cancer. Between 2005 and 2016, a single center, prospective cohort study was performed in Guadeloupe, French West Indies, including patients on active surveillance who had low risk prostate cancer (prostate specific antigen 10 ng/ml or less and Gleason score 6 or less) or favorable intermediate risk prostate cancer (prostate specific antigen 10 to 20 ng/ml, Gleason score 3 + 4 or less and life expectancy less than 10 years). Treatment was recommended in case of grade progression, increased tumor volume, prostate cancer doubling time less than 36 months or patient wish. Overall survival, disease specific survival and duration of active surveillance were calculated with the KaplanMeier method. Multivariate analysis was performed using the Cox proportional hazards model to identify predictors of active surveillance termination. A total of 234 patients with a median age of 64 years were enrolled in study. Median followup was 4 years (IQR 2.3-5.5). Overall survival at 30 months, 5 years and 10 years was 99.5%, 98.5% and 90.7%, respectively. Disease specific survival at 30 months, and 5 and 10 years was 100%. At 30 months, 5 years and 10 years 72.7%, 52.6% and 40.4% of patients, respectively, remained untreated and on active surveillance. Age (HR 0.96 per additional year, 95% CI 0.93-0.99) and prostate specific antigen density (HR 1.52 per additional 0.1 ng/ml, 95% CI 1.20-1.89) were found to be independent predictors of active surveillance termination. Active surveillance is safe and beneficial for highly selected African Caribbean patients. It seems to be feasible for patients at low risk and intermediate favorable risk."

According to the news editors, the research concluded: "Prostate specific antigen density could help better select these patients."

For more information on this research see: Active Surveillance for Favorable Risk Prostate Cancer in African Caribbean Men: Results of a Prospective Study. Journal of Urology, 2017;197(5):1229-1235. Journal of Urology can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (Elsevier -; Journal of Urology -

Our news journalists report that additional information may be obtained by contacting M. Meunier, Pointe A Pitre Univ Hosp, Inst Natl Sante & Rech Med, Dept. of Urol, IRSETU1085, Pointe a Pitre, Guadeloupe, Guadeloupe. Additional authors for this research include R. Eyraud, C. Senechal, G. Gourtaud, V. Roux, C. Lanchon, L. Brureau and P. Blanchet (see also Oncology - Prostate Cancer).

Keywords for this news article include: Pointe a Pitre, Guadeloupe, North and Central America, Clinical Trials and Studies, Prostate-Specific Antigen, Enzymes and Coenzymes, Cancer, Epidemiology, Prostatic Neoplasms, Peptide Hydrolases, Clinical Research, Serine Proteases, Prostate Cancer, Endopeptidases, Kallikreins, Oncology, Department of Urology.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


Central America
North America
United States
New York
New York City


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Pharmaceutical Development
      Medical Specialties and Practices
      Treatments and Therapies